Roche seen upping $42 billion Genentech bid after rebuff

ZURICH (Reuters) – Roche will likely have to up its bid for the 44 percent of Genentech it does not already own, analysts said on Tuesday, after the U.S. biotech group urged shareholders to reject the offer.

Leave a Reply